{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:14:29Z","timestamp":1788300869405,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int.J. Behav. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Familial hypercholesterolemia (FH) is a common genetic condition associated with lifelong hypercholesterolemia and increased risk of premature cardiovascular disease. Genetic cascade testing, the systematic identification and testing of at-risk blood relatives of a diagnosed index case, enables early detection and intervention but remains underutilized in primary care. This study explored the experiences of patients and general practitioners (GPs) involved in FH genetic cascade testing to identify barriers and facilitators to implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A mixed-methods study was conducted using semi-structured interviews with adults diagnosed with FH and parents of children with FH, alongside open-ended questionnaires completed by GPs. Data were collected following delivery of the Enhanced Detection of FH in General Practice (EDIFICE) program and analyzed using reflexive thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients and 12 GPs participated. Themes included knowledge and understanding of FH, communication and testing challenges, emotional impacts, professional confidence, and system-level barriers. Patients reported variable understanding of FH, distress associated with diagnosis, and difficulties navigating healthcare pathways. GPs recognized the value of cascade testing but identified knowledge gaps, limited communication with specialists, and uncertainty regarding pediatric case management. Both groups highlighted the need for improved educational resources and streamlined referral processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FH genetic cascade testing in primary care is a valuable but underused strategy for early cardiovascular risk reduction. Improving practitioner training, patient education, and healthcare system integration may enhance implementation and uptake.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12529-026-10485-z","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:23:05Z","timestamp":1787170985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing Genetic Cascade Testing for Familial Hypercholesterolemia in Primary Care: Patient and General Practitioner Experiences"],"prefix":"10.1007","author":[{"given":"Charlene","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Della-Vedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Hagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"1","key":"10485_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","volume":"168","author":"D Marks","year":"2003","unstructured":"Marks D, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1\u201314.","journal-title":"Atherosclerosis"},{"issue":"9","key":"10485_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016461","volume":"7","author":"LE Akioyamen","year":"2017","unstructured":"Akioyamen LE, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;7(9):e016461.","journal-title":"BMJ Open"},{"issue":"45","key":"10485_CR3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478\u201390.","journal-title":"Eur Heart J"},{"issue":"2","key":"10485_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.amjcard.2011.03.027","volume":"108","author":"A Elis","year":"2011","unstructured":"Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol. 2011;108(2):223\u20136.","journal-title":"Am J Cardiol"},{"issue":"3","key":"10485_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1017\/S1047951113000528","volume":"24","author":"A Elis","year":"2014","unstructured":"Elis A, Zhou R, Stein EA. Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiol Young. 2014;24(3):437\u201341.","journal-title":"Cardiol Young"},{"issue":"720","key":"10485_CR6","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.3399\/BJGP.2021.0558","volume":"72","author":"L Silva","year":"2022","unstructured":"Silva L, et al. Introducing genetic testing with case finding for familial hypercholesterolaemia in primary care: qualitative study of patient and health professional experience. Br J Gen Pract. 2022;72(720):e519\u201327.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"10485_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.hlc.2019.12.002","volume":"29","author":"J Pang","year":"2020","unstructured":"Pang J, et al. Familial hypercholesterolaemia in 2020: a leading tier 1 genomic application. Heart Lung Circ. 2020;29(4):619\u201333.","journal-title":"Heart Lung Circ"},{"key":"10485_CR8","unstructured":"Australian Government Department of Health. MBS online medicare benefits schedule. 2020. https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73352&qt=item&criteria=73352.\u00a0Accessed 20 Dec 2025."},{"key":"10485_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2018.08.019","volume":"277","author":"T Brett","year":"2018","unstructured":"Brett T, et al. Screening for familial hypercholesterolaemia in primary care: time for general practice to play its part. Atherosclerosis. 2018;277:399\u2013406.","journal-title":"Atherosclerosis"},{"issue":"3","key":"10485_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/gim.2014.101","volume":"17","author":"NA Mikat-Stevens","year":"2015","unstructured":"Mikat-Stevens NA, Larson IA, Tarini BA. Primary-care providers\u2019 perceived barriers to integration of genetics services: a systematic review of the literature. Genet Med. 2015;17(3):169\u201376.","journal-title":"Genet Med"},{"issue":"1","key":"10485_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12529-014-9402-x","volume":"22","author":"SJ Hardcastle","year":"2015","unstructured":"Hardcastle SJ, et al. Patients\u2019 perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int J Behav Med. 2015;22(1):92\u2013100.","journal-title":"Int J Behav Med"},{"key":"10485_CR12","doi-asserted-by":"publisher","unstructured":"Pang J, et al. Enhancing the detection of familial hypercholesterolaemia in general practice: a model for supporting genetic cascade testing in the community. Eur J Hum Genet. 2026;34:252\u2013259. https:\/\/doi.org\/10.1038\/s41431-025-01979-7.","DOI":"10.1038\/s41431-025-01979-7"},{"issue":"6","key":"10485_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"10485_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292:114523.","journal-title":"Soc Sci Med"},{"issue":"13","key":"10485_CR15","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"key":"10485_CR16","doi-asserted-by":"publisher","DOI":"10.4135\/9781473906907","volume-title":"Using software in qualitative research: a step-by-step guide","author":"C Silver","year":"2014","unstructured":"Silver C, Lewins A. Using software in qualitative research: a step-by-step guide. 2014."},{"key":"10485_CR17","unstructured":"Braun V, Clarke V. Successful qualitative research: a practical guide for beginners. 2013. p. 48\u201350."},{"issue":"2","key":"10485_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"4","key":"10485_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health. 2019;11(4):589\u201397.","journal-title":"Qual Res Sport Exerc Health"},{"key":"10485_CR20","doi-asserted-by":"crossref","unstructured":"Hagger MS, Cameron LD, Hamilton K, Hankonen N, Lintunen T, editors. The handbook of behavior change. Cambridge University Press.\u00a02020.","DOI":"10.1017\/9781108677318"},{"key":"10485_CR21","doi-asserted-by":"crossref","unstructured":"Marteau TM, et al. Changing behavior by changing environments. In: Hagger MS, et al.\u00a0editor., The handbook of behavior change. Cambridge: Cambridge University Press; 2020. p. 193\u2013207.","DOI":"10.1017\/9781108677318.014"},{"issue":"4","key":"10485_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.hlc.2013.08.005","volume":"23","author":"DA Bell","year":"2014","unstructured":"Bell DA, et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ. 2014;23(4):309\u201313.","journal-title":"Heart Lung Circ"},{"issue":"8","key":"10485_CR23","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1093\/pch\/pxy033","volume":"23","author":"I Tremblay","year":"2018","unstructured":"Tremblay I, Janvier A, Laberge A-M. Paediatricians underuse recommended genetic tests in children with global developmental delay. Paediatr Child Health. 2018;23(8):e156-62.","journal-title":"Paediatr Child Health"},{"issue":"10","key":"10485_CR24","first-page":"e626","volume":"62","author":"JC Carroll","year":"2016","unstructured":"Carroll JC, et al. Primary care providers\u2019 experiences with and perceptions of personalized genomic medicine. Can Fam Physician. 2016;62(10):e626\u201335.","journal-title":"Can Fam Physician"},{"issue":"8","key":"10485_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/jpc.16096","volume":"58","author":"AE Horton","year":"2022","unstructured":"Horton AE, et al. Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: practical advice for the community clinician. J Paediatr Child Health. 2022;58(8):1297\u2013312.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"10485_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","volume":"30","author":"GF Watts","year":"2021","unstructured":"Watts GF, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ. 2021;30(3):324\u201349.","journal-title":"Heart Lung Circ"},{"issue":"2","key":"10485_CR27","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/j.jacl.2024.01.001","volume":"18","author":"LK Jones","year":"2024","unstructured":"Jones LK, et al. Using implementation science to develop a familial hypercholesterolemia screening program in primary care: the CARE-FH study. J Clin Lipidol. 2024;18(2):e176-88.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10485_CR28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","volume":"17","author":"GF Watts","year":"2020","unstructured":"Watts GF, et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020;17(6):360\u201377.","journal-title":"Nat Rev Cardiol"},{"key":"10485_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100710","volume":"19","author":"K Kim","year":"2024","unstructured":"Kim K, et al. Primary care clinician engagement in implementing a machine-learning algorithm for targeted screening of familial hypercholesterolemia. Am J Prev Cardiol. 2024;19:100710.","journal-title":"Am J Prev Cardiol"},{"issue":"4","key":"10485_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10897-010-9296-y","volume":"19","author":"K Chivers Seymour","year":"2010","unstructured":"Chivers Seymour K, et al. What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns. 2010;19(4):330\u201342.","journal-title":"J Genet Couns"},{"issue":"7","key":"10485_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/tbm\/ibac018","volume":"12","author":"G Campbell-Salome","year":"2022","unstructured":"Campbell-Salome G, et al. Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication. Transl Behav Med. 2022;12(7):800\u20139.","journal-title":"Transl Behav Med"},{"issue":"1","key":"10485_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13073-021-00887-x","volume":"13","author":"ML Hallquist","year":"2021","unstructured":"Hallquist ML, et al. Application of a framework to guide genetic testing communication across clinical indications. Genome Med. 2021;13(1):71.","journal-title":"Genome Med"},{"key":"10485_CR33","doi-asserted-by":"publisher","unstructured":"Cormack M, et al. Mainstreaming genomic testing: pre\u2010test counselling and informed consent. Med J Aust. 2024;220:403\u2013406. https:\/\/doi.org\/10.5694\/mja2.52254.","DOI":"10.5694\/mja2.52254"},{"issue":"1","key":"10485_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12875-016-0483-2","volume":"17","author":"M Paneque","year":"2016","unstructured":"Paneque M, et al. A systematic review of interventions to provide genetics education for primary care. BMC Fam Pract. 2016;17(1):89.","journal-title":"BMC Fam Pract"},{"issue":"10","key":"10485_CR35","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.gim.2022.07.003","volume":"24","author":"JC Carroll","year":"2022","unstructured":"Carroll JC, et al. Use of eConsult to enhance genetics service delivery in primary care: a multimethod study. Genet Med. 2022;24(10):2034\u201341.","journal-title":"Genet Med"},{"key":"10485_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100344","volume":"10","author":"LK Jones","year":"2022","unstructured":"Jones LK, et al. Patient experiences align with the familial hypercholesterolemia global call to action. Am J Prev Cardiol. 2022;10:100344.","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10485_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/00178969211055976","volume":"81","author":"S McIntosh","year":"2022","unstructured":"McIntosh S, et al. Patient voice and health education for familial hypercholesterolaemia. Health Educ J. 2022;81(2):123\u201333.","journal-title":"Health Educ J"},{"issue":"1","key":"10485_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12687-022-00620-0","volume":"14","author":"H Massey","year":"2023","unstructured":"Massey H, Jennings B, Miedzybrodzka Z. Understanding how educational interventions improve treatment adherence in patients with familial hypercholesterolaemia: a systematic review. J Community Genet. 2023;14(1):5\u201315.","journal-title":"J Community Genet"},{"key":"10485_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2021.100245","volume":"8","author":"CL Jackson","year":"2021","unstructured":"Jackson CL, et al. Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: a simulation analysis. Am J Prev Cardiol. 2021;8:100245.","journal-title":"Am J Prev Cardiol"},{"issue":"4","key":"10485_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","volume":"8","author":"Z Ademi","year":"2014","unstructured":"Ademi Z, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8(4):390\u2013400.","journal-title":"J Clin Lipidol"},{"issue":"23","key":"10485_CR41","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/eurheartj\/ehx111","volume":"38","author":"M Kerr","year":"2017","unstructured":"Kerr M, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38(23):1832\u20139.","journal-title":"Eur Heart J"},{"key":"10485_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2018.05.047","volume":"275","author":"AJ McKay","year":"2018","unstructured":"McKay AJ, et al. Universal screening at age 1\u20132 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis. 2018;275:434\u201343.","journal-title":"Atherosclerosis"},{"issue":"5","key":"10485_CR43","first-page":"464","volume":"29","author":"A Rosso","year":"2017","unstructured":"Rosso A, et al. The cost-effectiveness of genetic screening for familial hypercholesterolemia: a systematic review. Ann Ig. 2017;29(5):464\u201380.","journal-title":"Ann Ig"},{"issue":"36","key":"10485_CR44","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425\u201337.","journal-title":"Eur Heart J"},{"issue":"7","key":"10485_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038458","volume":"14","author":"SS Gidding","year":"2025","unstructured":"Gidding SS, et al. Life course approach for managing familial hypercholesterolemia. J Am Heart Assoc. 2025;14(7):e038458.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10485_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","volume":"20","author":"GF Watts","year":"2023","unstructured":"Watts GF, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023;20(12):845\u201369.","journal-title":"Nat Rev Cardiol"}],"container-title":["International Journal of Behavioral Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12529-026-10485-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12529-026-10485-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12529-026-10485-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:30:46Z","timestamp":1788298246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12529-026-10485-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":46,"alternative-id":["10485"],"URL":"https:\/\/doi.org\/10.1007\/s12529-026-10485-z","relation":{},"ISSN":["1070-5503","1532-7558"],"issn-type":[{"value":"1070-5503","type":"print"},{"value":"1532-7558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Royal Perth Hospital Human Research Ethics Committee (RGS5627).","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}